Loading...
Distinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA
BACKGROUND: Canakinumab is a human anti-IL-1β blocking agent that effectively neutralizes IL-1β mediated signaling for treatment of systemic juvenile idiopathic arthritis (sJIA). While many patients have dramatic clinical response to IL-1 blockade, approximately one-third fail to respond, but there...
Na minha lista:
| Udgivet i: | Arthritis Rheumatol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8238800/ https://ncbi.nlm.nih.gov/pubmed/33452871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41640 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|